Changeflow GovPing Pharma & Drug Safety Compositions and Methods for Decolonizing Antib...
Routine Notice Added Final

Compositions and Methods for Decolonizing Antibiotic-Resistant Bacteria in the Gut

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Peptides (C07K)
Published March 25th, 2026
Detected April 1st, 2026
Email

Summary

The European Patent Office published patent application EP3665181A1 for Finch Therapeutics' compositions and methods for decolonizing antibiotic-resistant bacteria in the gut. The patent covers therapeutic compositions and methods of use targeting antibiotic-resistant bacterial colonization. The application was filed with claims across 39 designated European states.

What changed

The EPO published EP3665181A1, a patent application by Finch Therapeutics, Inc. covering compositions and methods for decolonizing antibiotic-resistant bacteria in the gastrointestinal tract. The patent includes claims under multiple IPC classifications including C07K (peptides), A61K (pharmaceutical preparations), and A61P (therapeutic activity). Inventors listed are Marina Santiago and Kevin Roelofs. The application designates 39 European states including major markets DE, FR, GB, IT, ES, NL, and CH.

Healthcare providers and pharmaceutical companies developing microbiome-based therapeutics should review this patent landscape to identify potential licensing needs or freedom-to-operate concerns. Intellectual property professionals should conduct clearance searches for similar composition claims. The patent provides Finch Therapeutics with exclusive rights to its decolonization technology across designated EPO member states upon grant.

What to do next

  1. Review patent claims for potential freedom-to-operate concerns if developing similar microbiome therapeutics
  2. Conduct landscape analysis for competing patents in gut decolonization technology
  3. Monitor patent prosecution for scope changes during examination

Source document (simplified)

← EPO Patent Bulletin

COMPOSITIONS AND METHODS FOR DECOLONIZING ANTIBOTIC-RESISTANT BACTERIA IN THE GUT

Publication EP3665181A1 Kind: A1 Mar 25, 2026

Applicants

Finch Therapeutics, Inc.

Inventors

SANTIAGO, Marina, ROELOFS, Kevin

IPC Classifications

C07H 21/02 20060101AFI20210503BHEP C07H 21/04 20060101ALI20210503BHEP C07K 14/25 20060101ALI20210503BHEP C12P 19/34 20060101ALI20210503BHEP A61K 35/74 20150101ALI20210503BHEP A61P 1/00 20060101ALI20210503BHEP A61P 1/04 20060101ALI20210503BHEP A61P 31/04 20060101ALI20210503BHEP C12R 1/01 20060101ALI20210503BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

Compositions for Decolonizing Antibiotic-Resistant Bacteria Methods of Use

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
EPO
Published
March 25th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3665181A1

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Clinical investigators
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology 6211 Healthcare Providers
Activity scope
Pharmaceutical Patent Prosecution Intellectual Property Licensing Biotechnology Research
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Healthcare Anti-Money Laundering

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Peptides (C07K) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.